<DOC>
	<DOCNO>NCT00403650</DOCNO>
	<brief_summary>This trial study treatment sarcoidosis-associated pulmonary arterial hypertension inhale iloprost , drug approve primary pulmonary arterial hypertension .</brief_summary>
	<brief_title>Inhaled Iloprost Sarcoidosis-associated Pulmonary Hypertension</brief_title>
	<detailed_description>Pulmonary hypertension describe sarcoidosis . It significant problem , responsive treatment anti-inflammatory drug sarcoidosis ( 1 ; 2 ) . Inhaled iloprost approve treatment pulmonary hypertension ( 3 ) . We propose study effectiveness inhale iloprost sarcoidosis associate pulmonary hypertension ( SAPAH ) . This open label trial , patient receive 16 week therapy . Clinical hemodynamic outcome therapy assess .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Patients know sarcoidosis 17 Age 18 great Patients document pulmonary hypertension PA mean &gt; 25 mm measure cardiac catheterization within six month entry study Patients dyspnea Six minute walk distance 100 500 meter Patients stable immunotherapy sarcoidosis , include prednisone , methotrexate , azathioprine , hydroxychloroquine , cyclophosphamide , thalidomide , and/or infliximab Patients able provide write consent Patients pulmonary vasodilator drug ( flolan , remodulin , bosentan , sildenafil ) prior 28 day ( patient stable dose calcium channel blocker 1 month prior right heart catheterization continue calcium channel blocker ) Patients severe airway obstruction define FEV1/FVC le 35 % Patients World Health Organization ( WHO ) class IV status Patients pregnant breast feeding Patients significant leave ventricular dysfunction leave ventricular ejection fraction le 35 % Significant liver dysfunction due sarcoidosis Patients severe organ disease felt investigator impact survival course study Patients unable perform 6 inhalation treatment require therapy Patients &lt; 90 mm Hg Systolic systemic blood pressure exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Sarcoidosis</keyword>
	<keyword>Dyspnea</keyword>
	<keyword>Interstitial lung disease</keyword>
</DOC>